Donate For Public and Patients Store Search

S036 - Psoriasis

Saturday, March 2; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify the best treatment for each psoriasis patient
  • Treat psoriasis in a pregnancy and women of childbearing potential
  • Treat psoriasis in a patient with a prior malignancy

Description

This session will review the most up to date information on the treatment of psoriasis patients including the pipeline of new therapeutic agents and a strategy of selecting the very best drug for each patient. The treatment of psoriasis in special populations including women of childbearing potential, pregnant women and children can be challenging. The latest from the new Guidelines of Care for these populations will be included. What do you need to know about the risk of malignancy with biologic therapy? Should you treat to target? Will treatment influence the cardiovascular comorbidities?

Disclosures

  • Armstrong, April W., MD, MPH: AbbVie – A(H), C(H), Data Safety Monitoring Board(H), I(Grants/Research Funding), SP(H); Amgen – A(H); Boehringer Ingelheim – Data Safety Monitoring Board(H); Bristol-Myers Squibb – C(H), I(Grants/Research Funding); Celgene – C(H), I(Grants/Research Funding); Demira – I(Grants/Research Funding); Dermavant Sciences – C(H); Eli Lilly and Company – C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – C(H); Genzyme Corporation – C(H); GlaxoSmithKline – C(H); Janssen Pharmaceuticals, Inc – C(H), SP(H); Janssen-Ortho Inc. – A(H), C(H), I(Grants/Research Funding); Leo Pharma Inc – C(H), I(Grants/Research Funding); Menlo Therapeutics – C(H); Merck & Co., Inc – A(H); Modernizing Medicine – C(H); NIH – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), C(H), I(Grants/Research Funding); Ortho Dermatologics – C(H); Parexel – Data Safety Monitoring Board(H); Pfizer Inc. – A(H), C(H); Regeneron – C(H), I(NC); Regeneron Pharmaceuticals, Inc. – SP(H); Sanofi – I(NC), SP(H); Science 37, Inc. – C(H); UCB – A(H), I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(H);
  • Blauvelt, Andrew, MD: AbbVie – A(H), C(H), I(Fees), SP(H); Aclaris Therapeutics Inc. – A(H), C(H), I(Fees); Akros Pharma, Inc. – A(H), C(H); Allergan, Inc – A(H), C(H), I(Fees); Almirall – A(H), C(H); Amgen – A(H), C(H), I(Fees); Arena Pharmaceuticals – A(H), C(H); Athenex – A(H), C(H), I(Fees); Boehringer Ingelheim – A(H), C(H), I(Fees); Bristol-Myers Squibb – A(H), C(H); Celgene – A(H), C(H), I(Fees); Dermavant Sciences – A(H), C(H), I(Fees); Dermira – A(H), C(H), I(Fees); Eli Lilly and Company – A(H), C(H), I(Fees); FLX Bio – A(H), C(H); Forte Biosciences – A(H), C(H); Galderma Laboratories, L.P. – A(H), C(H); Galderma USA – I(Fees); Genentech, Inc. – A(H), C(H), I(Fees); GlaxoSmithKline – A(H), C(H), I(Fees); Janssen-Ortho Inc. – A(H), C(H), I(Fees), SP(H); Leo Pharma Inc – A(H), C(H), I(Fees); Meiji Seika Pharma Co., Ltd – A(H), C(H); Merck & Co., Inc – A(H), C(H), I(Fees); Novartis Pharmaceuticals Corp. – A(H), C(H), I(Fees); Pfizer Inc. – A(H), C(H), I(Fees); Purdue Pharma – A(H), C(H); Regeneron – A(H), C(H), I(Fees), SP(H); Revance Therapeutics, Inc. – I(Fees); Sandoz, a Novartis company – A(H), C(H), I(Fees); Sanofi – A(H), C(H), SP(H); Sienna Biopharmaceuticals – A(H), C(H), I(Fees); Sun Pharmaceutical Industries Ltd. – A(H), C(H); UCB – A(H), C(H), I(Fees); Valeant Pharmaceuticals International – A(H), C(H), I(Fees); Vidac Pharma – A(H), C(H), I(Fees);
  • Cordoro, Kelly M., MD: Celgene Corporation – C(Fees);
  • Elewski, Boni E., MD: AbbVie – I(Grants/Research Funding); AnaptysBio – I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – I(Grants/Research Funding); Celgene Corporation – C(H), I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – A(H); Incyte Corporation – I(Grants/Research Funding); InflaRx GmbH – I(Grants/Research Funding); Janssen-Ortho Inc. – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – A(H), I(Grants/Research Funding); Lilly ICOS LLC – C(H); Menlo Therapeutics – I(Grants/Research Funding); Merck & Co., Inc – I(Grants/Research Funding); Novan – C(H); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H), I(Grants/Research Funding); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding); Verrica Pharmaceuticals Inc – A(H);
  • Gordon, Kenneth B., MD: AbbVie – C(H), I(Grants/Research Funding); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Celgene Corporation – A(H), I(Grants/Research Funding); Demira – C(H); Dermavant Sciences – C(H); Eli Lilly and Company – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – C(H); Leo Pharma Inc – C(H); Lilly ICOS LLC – A(H); Novartis – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H); Othro Dermatologics – C(H); Pfizer Inc. – A(H); Sun Pharmaceutical Industries Ltd. – C(H); UCB – C(H);
  • Kimball, Alexandra Boer, MD, MPH: AbbVie – C(H), I(Grants/Research Funding), I(Residency/Fellowship Program Funding); Almirall – C(H); BMS – C(H); Escalier Biosciences – A(H), A(OB); Janssen Biotech – C(H); Janssen Pharmaceuticals, Inc – I(Residency/Fellowship Program Funding); Lilly ICOS LLC – C(H); Novartis – C(H), I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Procter & Gamble Company – C(H); Regeneron – C(H); Sanofi/Regeneron – C(H); UCB – C(H); Unilever – A(H); Vimalan Biosciences, Inc. – A(H), A(SO);
  • Langley, Richard G. B., MD: AbbVie – A(H), I(Grants/Research Funding), SP(H); Amgen – I(Grants/Research Funding), SP(H); Astellas Pharma US, Inc – I(Grants/Research Funding); Boehringer Ingelheim – A(H), I(Grants/Research Funding); Celgene Corporation – A(H); Centocor Ortho Biotech Inc. – A(H), I(Grants/Research Funding); Eli Lilly and Company – A(H), I(H); Genentech, Inc. – I(Grants/Research Funding); Isotechnika Pharma Inc. – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – I(Grants/Research Funding); Merck Serono – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding), SP(H);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Almirall – C(H); Amgen – I(Grants/Research Funding); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Avotres, Inc. – C(H); BirchBioMed – C(H); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Cara Therapeutics – C(H); Castle Biosciences, Inc – C(H); Celgene Corporation – I(Grants/Research Funding); Clinuvel – I(Grants/Research Funding); Corrona, Inc. – O(H); Dermavant Sciences – C(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Inozyme Pharma – C(H); Janssen Research & Development, LLC – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); LEO Pharma, US – I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Meiji Seika Pharma Co., Ltd – C(H); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Neuroderm LTD – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Ortho Dermatologics – I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Verrica Pharmaceuticals Inc – C(H); Vidac Pharma – I(Grants/Research Funding);
  • Wu, Jashin J., MD: C(H), I(Grants/Research Funding); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding); BMS – C(H); Celgene – C(H), SP(H); Demira – C(H); Dr Reddy's Laboratory – C(H); Eli Lilly and Company – C(H), I(Grants/Research Funding); Janssen Biotech – C(H); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Leo Pharma Inc – C(H); Novartis – C(H), I(Grants/Research Funding), SP(H); Ortho Dermatologics – C(H); Pfizer Inc. – C(H); Promius Pharma, LLC – C(H); Regeneron – C(H), SP(H); Sanofi Genzyme – SP(H); Sun Pharmaceutical Industries Ltd. – C(H), SP(H); UCB – C(H), SP(H); Valeant Pharmaceuticals North America LLC – C(H), SP(H);
Schedule
Saturday, March 2
1:00 PM
Dr. Elewski / Welcome and Overview
1:05 PM
Dr. Lebwohl / Treatment of psoriasis: Which drug for which patient?
1:25 PM
Dr. Blauvelt / Pipeline of new therapeutic agents
1:45 PM
Dr. Kimball / Treatment of psoriasis in pregnancy
2:05 PM
Dr. Cordoro / Treatment of pediatric psoriasis: Update on new guidelines of care
2:25 PM
Dr. Wu / Does psoriasis treatment influence the cardiovascular comorbidities?
2:45 PM
Dr. Langley / Treat to Target: Of course, we should!
2:57 PM
Dr. Gordon / Treat to Target: No, not necessarily!
3:09 PM
Dr. Langley and Dr. Gordon / Rebuttals and Audience voting
3:25 PM
Dr. Strober / The risk of malignancy with biologic therapy for psoriasis
3:45 PM
Dr. Blauvelt, Dr. Wu, Dr. Langley, Dr. Gordon, Dr. Elewski, and Dr. Armstrong / Panel discussion
Event Details
  • Date
    Saturday, March 2
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 146B
  • CME Credits
    3.00
  • Type
    MOC
Directors/Co-Directors
  • Boni E. Elewski, MD, FAAD
Speakers
  • Alexandra Boer Kimball, MD, MPH, FAAD
  • Andrew Blauvelt, MD, FAAD - Handout
  • April W. Armstrong, MD, MPH, FAAD
  • Jashin J. Wu, MD, FAAD - Handout
  • Kelly M. Cordoro, MD, FAAD - Handout
  • Kenneth B. Gordon, MD, FAAD
  • Mark Lebwohl, MD, FAAD - Handout
  • Richard G. B. Langley, MD, FAAD